Celcuity Inc. (Nasdaq: CELC) is a clinical-stage biotechnology company focused on the development of targeted therapies for a number of different cancers. Our mission is to extend the lives of cancer patients by developing potential first-in-class therapies and companion diagnostics.
Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is conducting a Phase 3 registration-enabling clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. Our CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies.
Data Provided by Quotemedia with delay
There are currently no events to display.
August 10, 2022 at 11:30 AM ET
November 17, 2022
June 1, 2022
19th Annual Craig-Hallum Institutional Investor Conference
June 9, 2022 at 2:30 PM ET
Jefferies Healthcare Conference
May 16, 2022 at 4:30 PM ET
Celcuity First Quarter 2022 Financial Results Webcast/Conference Call
March 23, 2022 at 4:30 PM ET
Celcuity Fourth Quarter and Full Year 2021 Financial Results Conference Call